Skye Bioscience nears Phase IIa data for nimacimab, targeting obesity treatment gaps with robust preclinical insights.

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Net Loss: Net loss for the three months ended June 30, 2025, totaled $17.6 million, with non-cash stock-based compensation expense of $4.2 million, compared to $7.9 million for the same period in 2024 ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...